SMITHS FALLS,
ON and MONTREAL, Sept. 26,
2019 /CNW/ - Spectrum Therapeutics ("Spectrum"), the
medical division of Canopy Growth Corporation (TSX: WEED) (NYSE:
CGC) is pleased to announce a donation to the Fondation de
l'Hôpital du Sacré-Coeur de Montreal (Montreal Sacre Coeur Hospital
Foundation) to support the Canadian Sleep and Circadian Network's
("CSCN") associated national campaign: Sleep On It
which aims to raise awareness about the importance of good
quality sleep on health.
Spectrum's donation to the campaign has been made, based on
CSCN's request to support their initiative to organize the sleep
scientific community around the question of cannabis use for sleep
disorders. Although an increasing volume of anecdotal data
indicates the growing usage of cannabis from individuals coping
with sleep disorders, clinical scientific evidence on its
effectiveness is still limited. Hence, via this donation, CSCN will
be able to provide to the public, health management decision makers
as well as the sleep scientific community, a review of currently
available data and identify the research gaps that need to be
filled. This review is expected to be completed during the second
half of the 2020 calendar year.
By partnering with the leader in the cannabis industry, CSCN's
objective is to combine the expertise of clinicians, physicians and
researchers across the country to facilitate and scientifically
support the development of a white paper based on a comprehensive
review of all existing literature and facts about the use of
cannabis in sleep disorder management. The report is also expected
to be published during the second half of the 2020 calendar year
and will introduce an updated clinical research program looking at
all areas that impact quality of sleep, including pain, aging, and
sleep disorders such as insomnia. Ultimately, the white paper will
provide insights and guidance on future research directions and
further requirements for evidence on the potential application of
medical cannabis in treating sleep disorders.
"Good quality sleep is far more important to our long-term
health than most people realize," commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth.
"We're just now beginning to explore the role cannabis can play in
addressing sleep-related disorders. Patient feedback is very
promising so far, and partnerships such as these will advance our
understanding of the intriguing phenomenon of sleep that is so
essential to our overall well-being."
"The legalization of cannabis in Canada has brought about a natural interest in
the potential for cannabis in the treatment of sleeping disorders.
We need to catalyze the development of collective efforts to
further develop scientific knowledge platforms to inform policy,
therapeutic practice, and prevention efforts about sleep and
cannabis and to scientifically inform decision makers as well as
general public about the research needs to produce evidence based
data on sleep and cannabis," commented Dr Julie Carrier, Scientific director of the
Canadian Sleep & Circadian Network and sleep researcher at the
CIUSSS du Nord-de-l'Île-de-Montreal.
One in three Canadians don't get the recommended seven hours of
sleep each night. The CSCN's mission is to mobilize the healthcare
community to adopt an integrated approach towards improving
outcomes and treatment of patients with sleep disorders.
Here's to Future Growth (and better sleep!)
About Canadian Sleep and Circadian Network
The
Canadian Sleep and Circadian Network (CSCN) is national in scope
and is committed to scientific excellence in the generation of new
knowledge and its translation. We look to better understand sleep
disruption and its impact so we can foster healthier sleep and
healthier Canadians.
About Spectrum Therapeutics
Spectrum Therapeutics, the
medical division of Canopy Growth Corporation (TSX: WEED, NYSE:
CGC), is dedicated to educating healthcare practitioners,
furthering the public's understanding of medical cannabis and its
various applications, and cutting edge, commercializable research
and IP development. Founded in Canada, Spectrum Therapeutics operates in
Australia, South America, Africa and across Europe. Its products are available in a wide
range of potencies and formats designed to simplify the dialogue
around strength and dosage by applying a colour-coded spectrum to
categorize medical cannabis according to THC and CBD levels.
Spectrum Therapeutics' offerings include whole flower cannabis,
oils and new innovations such as Softgels in addition to single
cannabinoid medicine Dronabinol under the brand Bionorica Ethics.
Through product simplification, robust clinical research and
ongoing education of healthcare professionals, Spectrum
Therapeutics is committed to addressing the unmet medical needs of
patients around the globe.
About Canopy Growth Corporation
Canopy Growth
(TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp
and cannabis device company, offering distinct brands and curated
cannabis varieties in dried, oil and Softgel capsule forms, as well
as medical devices through the Company's subsidiary, Storz &
Bickel GMbH & Co. KG. From product and process innovation to
market execution, Canopy Growth is driven by a passion for
leadership and a commitment to building a world-class cannabis
company one product, site and country at a time. The Company has
operations in over a dozen countries across five continents. The
Company's medical division, Spectrum Therapeutics is proudly
dedicated to educating healthcare practitioners, conducting robust
clinical research, and furthering the public's understanding of
cannabis, and has devoted millions of dollars toward cutting edge,
commercializable research and IP development. Spectrum Therapeutics
sells a range of full-spectrum products using its colour-coded
classification Spectrum system as well as single cannabinoid
Dronabinol under the brand Bionorica Ethics. The Company operates
retail stores across Canada under
its award-winning Tweed and Tokyo Smoke banners. Tweed is a
globally recognized cannabis brand which has built a large and
loyal following by focusing on quality products and meaningful
customer relationships. From our historic public listing on the
Toronto Stock Exchange and New York Stock Exchange to our continued
international expansion, pride in advancing shareholder value
through leadership is engrained in all we do at Canopy Growth.
Canopy Growth has established partnerships with leading sector
names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and
Green House Seeds, and Fortune 500 alcohol leader Constellation
Brands, to name but a few. Canopy Growth operates eleven licensed
cannabis production sites with over 4.7 million square feet of
production capacity, including over one million square feet of GMP
certified production space. For more information visit
www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news
release contains "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995
and "forward-looking information" within the meaning of applicable
Canadian securities legislation. Often, but not always,
forward-looking statements and information can be identified by the
use of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements or information involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Canopy Growth or its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements or information contained in this news
release. Examples of such statements include "aims to raise
awareness about the importance of good quality sleep on health",
and "development of a white paper based on a comprehensive review
of all existing literature and facts" . Risks, uncertainties and
other factors involved with forward-looking information could cause
actual events, results, performance, prospects and opportunities to
differ materially from those expressed or implied by such
forward-looking information, including results of the research
review and such risks contained in the Company's annual information
form dated June 24, 2019 and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR at www.sedar.com. Although the Company
believes that the assumptions and factors used in preparing the
forward-looking information or forward-looking statements in this
news release are reasonable, undue reliance should not be placed on
such information and no assurance can be given that such events
will occur in the disclosed time frames or at all. The
forward-looking information and forward-looking statements included
in this news release are made as of the date of this news release
and the Company does not undertake an obligation to publicly update
such forward-looking information or forward-looking information to
reflect new information, subsequent events or otherwise unless
required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/spectrum-therapeutics-announces-donation-to-support-research-and-education-initiatives-led-by-the-canadian-sleep-and-circadian-network-300926073.html
SOURCE Spectrum Therapeutics